Biosimilar major Sandoz has started construction of an additional US$440m biosimilar facility near Ljubljana and it set to expand its investment footprint in Slovenia by US$1.1bn.
ADVERTISEMENT
ADVERTISEMENT
Log in here to read the desired article.
ADVERTISEMENT
Biosimilar major Sandoz has started construction of an additional US$440m biosimilar facility near Ljubljana and it set to expand its investment footprint in Slovenia by US$1.1bn.